Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000513467 | SCV000226341 | uncertain significance | not provided | 2017-01-10 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000193499 | SCV000249403 | uncertain significance | not specified | 2015-05-15 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000513467 | SCV000609315 | uncertain significance | not provided | 2017-05-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001047823 | SCV001211805 | uncertain significance | Cohen syndrome | 2023-12-11 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 692 of the VPS13B protein (p.Arg692Gln). This variant is present in population databases (rs371500701, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 194549). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt VPS13B protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000513467 | SCV002549358 | uncertain significance | not provided | 2022-07-14 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002415747 | SCV002729812 | uncertain significance | Inborn genetic diseases | 2018-08-04 | criteria provided, single submitter | clinical testing | The p.R692Q variant (also known as c.2075G>A), located in coding exon 14 of the VPS13B gene, results from a G to A substitution at nucleotide position 2075. The arginine at codon 692 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001047823 | SCV001456248 | uncertain significance | Cohen syndrome | 2020-04-15 | no assertion criteria provided | clinical testing | |
Genome |
RCV001047823 | SCV001749838 | not provided | Cohen syndrome | no assertion provided | phenotyping only | Variant interpreted as Uncertain significance and reported on 12-03-2019 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. | |
Prevention |
RCV004742311 | SCV005351145 | uncertain significance | VPS13B-related disorder | 2024-03-05 | no assertion criteria provided | clinical testing | The VPS13B c.2075G>A variant is predicted to result in the amino acid substitution p.Arg692Gln. This variant has been reported at a frequency of ~0.01% in individuals of European origin in a large population database and has been reported in ClinVar as uncertain (https://www.ncbi.nlm.nih.gov/clinvar). Based on these observations, the c.2075G>A variant is classified as uncertain. |